The Essential Biotech Investment Guide PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download The Essential Biotech Investment Guide PDF full book. Access full book title The Essential Biotech Investment Guide by Chilung Mark Tang. Download full books in PDF and EPUB format.
Author: Chilung Mark Tang
Publisher: World Scientific
ISBN: 9789812381392
Category : Business & Economics
Languages : en
Pages : 294
Get Book
Book Description
This invaluable book tells the reader how to invest in the healthcare biotechnology and life sciences sector, one of the fast-growing sectors of the US economy. Aimed at biotech investors as well as bioentrepreneurs and venture capitalists, it has been written from the perspectives of risk management and asset management/allocation. It strives to teach readers how to fish, rather than giving them fish. The author has over ten years of Wall Street experience in biotech research, investment banking and asset management. He holds an MBA in Finance and a PhD in Biochemistry.
Author: Chilung Mark Tang
Publisher: World Scientific
ISBN: 9789812381392
Category : Business & Economics
Languages : en
Pages : 294
Get Book
Book Description
This invaluable book tells the reader how to invest in the healthcare biotechnology and life sciences sector, one of the fast-growing sectors of the US economy. Aimed at biotech investors as well as bioentrepreneurs and venture capitalists, it has been written from the perspectives of risk management and asset management/allocation. It strives to teach readers how to fish, rather than giving them fish. The author has over ten years of Wall Street experience in biotech research, investment banking and asset management. He holds an MBA in Finance and a PhD in Biochemistry.
Author: Chilung Mark Tang
Publisher: Turtleback
ISBN: 9780613918671
Category : Business & Economics
Languages : en
Pages :
Get Book
Book Description
This invaluable book tells the reader how to invest in the healthcare biotechnology and life science sector, one of the fast-growing sectors of the US economy. Aimed at biotech investors as well as bioentrepreneurs and venture capitalists, it has been written from the perspectives of risk management and asset management. It strives to teach readers how to fish, rather than giving them fish. The author has over ten years of Wall Street experience in biotech research, investment banking and asset management. He holds an MBA in Finance and a PhD in Biochemistry.
Author: James D. Mccamant
Publisher: Basic Books
ISBN: 9780738205090
Category : Business & Economics
Languages : en
Pages : 208
Get Book
Book Description
Biotechnology is indisputably one of the fastest-growing and most promising industries. Virtually immune to swings in the economic cycles, biotech stocks continue to perform steadily as high-tech stocks lose their steam.In Biotech Investing, Jim McCamant offers proven strategies and savvy advice on how to capitalize on the unprecedented opportunities in this high-potential sector. Written by a recognized authority, this book dissects biotech business models from start-up to IPO and discusses in detail the most important factors that affect biotech research. Comprehensive in scope, it looks at the best and worst biotech contenders, discusses all the most newsworthy developments in the field, and shows how they translate into business success or failure. It outlines simple criteria for choosing the best biotech stocks and for understanding the sometimes complicated dynamics of this sector.
Author: George Wolff
Publisher: John Wiley & Sons
ISBN: 0471412791
Category : Business & Economics
Languages : en
Pages : 335
Get Book
Book Description
"The Biotech Investor's Bible" ist der maßgebliche Leitfaden für die Geldanlage in die zunehmend beliebteren, aber außerordentlich schwankungsanfälligen Biotechnologiewerte. Dieses einzigartige Buch erklärt die Grundlagen von Genetik, Patenten und Therapien und zeigt dem Anleger, wie er Biotechnologieunternehmen, deren Spitzentechnologie und neuesten Produkte bewertet. "The Biotech Investor's Bible" bietet eine interessante Zusammenfassung der relativ kurzen Geschichte dieses Industriezweiges und vermittelt einen umfassenden Überblick über verschiedene Branchenbereiche. Technologie und Wissenschaft des Biotechnologiemarktes werden zusammen mit detaillierten Investmentstrategien ausführlich erläutert. Autor George Wolff ist ein erfahrener Experte auf diesem Gebiet. "The Biotech Investor's Bible" ist eine unverzichtbare Lektüre für aktuelle und künftige Biotech-Anleger.
Author: Karl Keegan
Publisher: John Wiley & Sons
ISBN: 0470741341
Category : Business & Economics
Languages : en
Pages : 216
Get Book
Book Description
The first book to provide a simple and practical means of valuing biotech companies The book begins with a short history of the biotechnology industry; this is important as although it is about 30 years old, the first company went public only in 1996, so it is possible to plot the course of investment waves and dips It examines the European industry and its evolvement, and draws parallels between the similarities and differences between that and the US Looks at the various companies which make up the biotech industry (therapeutic; life sciences; and the medical technology company) and gives tools for the investor to properly evaluate them Praise for Biotechnology Valuation "Keegan states that the valuation of Biotech companies is as much an art as a science. This brief but comprehensive review of the skills and knowledge required, not of just the financial market and sentiment, but also of the technical attributes of a company and the drug development and regulatory hurdles that must be overcome, highlights the importance of the breadth of understanding required. Biotech investing is not for the timid, but it can bring substantial returns. Keegan's book, punctuated with his personal experience and opinions, is a good place to start." —Chris Blackwell, Chief Executive, Vectura Group plc "A user-friendly, yet thorough discussion of a notoriously difficult topic. Dr Keegan's book is a fine resource for both business types and academicians." —Steve Winokur, Managing Director, CanaccordAdams "A highly readable and comprehensive explanation of the technical and commercial parameters that influence biotechnology companies at all stages of development, providing clear context for selection from the toolkit of valuation methodologies the author recommends to assess company and product performance, or ascribe value." —Dr L.M. Allan, Director, Bioscience Enterprise Programme, University of Cambridge "A fabulous approach to a difficult topic." —Deirdre Y. Gillespie, MD, President & CEO, La Jolla Pharmaceutical Company
Author: Les Funtleyder
Publisher: McGraw Hill Professional
ISBN: 0071642951
Category : Business & Economics
Languages : en
Pages : 304
Get Book
Book Description
Is your portfolio in peak health? Ranking among the world's largest markets, the $2.5 trillion health care industry is growing at an unprecedented rate. According to Miller Tabak + Co.'s health care strategist Les Funtleyder, major structural renovations to the system are imminent. “Health care is entering an era of reform,” Funtleyder writes, “and with reform comes change and the opportunity for investment gain.” Health-Care Investing provides a thorough explanation of how the industry's mammoth size and complexity can be worked to your advantage and why health care is more resistant to changes in economic cycles than other markets. Funtleyder gives you a comprehensive overview of the industry, from both macro and micro points of view, so you can make informed decisions regarding your investments. You'll find critical information concerning The natural inelasticity of health care and how to profit from it How to take advantage of the market's complexities and inefficiencies Issues and policy changes you need to know The social responsibility aspect of investing in health care Why this market is essential for diversified portfolios In Health-Care Investing, Funtleyder provides the tools you need to dig up the richest opportunities possible and build them into your investment strategy. You'll get a detailed look at traditional market patterns and the events that have shaped--and will continue to shape--the industry. Then you'll find specific strategies you can use to maximize your profits, whether you invest in pharma, biotech, managed services, or a combination of them. This informative and practical guide also includes a list of questions you can use as an investment “template,” which will help guide your decision-making process. With Health Care Investing, you'll be armed with the know-how to make the right decisions today in order to fully capitalize on events of the future.
Author: Thomas Tscherning
Publisher:
ISBN: 9781596220317
Category : Business & Economics
Languages : en
Pages : 468
Get Book
Book Description
Gain access to biotech venture capital as efficiently as possible by doing the right things from the beginning of your fundraising. This book includes a collection of improvements that will increase your rate of success on receiving capital without loosing your shirt in the process. From how to make the biotech investor listen to you to the reasons deals get killed and everything in between, including a wealth of appendix material that guides readers through the basic slides of a presentation, the ins and outs of term sheets, key terms and more, this book is a must-read for anyone in need of funding. Topics covered include: - which business plans fail and why - understanding the interests of the investor - planning for solvency and liquidity - knowing and minimizing product risk - the value of a scientific advisory board - important points around patents - questions frequently posed by investors - questions to extend to biotech investors - what constitutes a good biotech deal - when is a bad time to try and close one - how to close your presentation, the deal and each round successfully and more.
Author: Tom Abate
Publisher: Times Books
ISBN: 146685121X
Category : Business & Economics
Languages : en
Pages : 308
Get Book
Book Description
A sophisticated investor's practical tool kit for analyzing the science, business, opportunities, and risks in the century's most promising industry The world is entering a biotechnology boom-but only informed investors will prosper in the incredibly complex biotech business. Separating the bioengineered wheat from the chaff, San Francisco Chronicle science and technology columnist Tom Abate, one of the top objective authorities on biotech, gives investors the analytical foundation to understand the science, finances, time horizon, and technological and commercial potential of this burgeoning industry. In The Biotech Investor, Abate provides sophisticated business analysis, guidelines for assessing company leadership, easy-to-digest reports from the labs, and indispensable investor tools and metrics. He explains how breaking news, medical conferences, U.S. Food and Drug Administration approvals, and the patent process affect investing strategies. Finally, he looks beyond medicine to review the financial opportunities presented by biotechnology advances in everything from agriculture to jean manufacturing, and shows investors how to identify "coattail" industries such as instrumentation and software development that will benefit from biotech successes. The Biotech Investor is the comprehensive, expert source for successful and intelligent investing in one of the twenty-first century's most promising industries.
Author: Scott Dessain
Publisher: Academic Press
ISBN: 0128092092
Category : Medical
Languages : en
Pages : 276
Get Book
Book Description
Preserving the Promise: Improving the Culture of Biotech Investment critically examines why most biotech startups fail, as they emerge from universities into an ecosystem that inhibits rather than encourages innovation. This "Valley of Death" squanders our public investments in medical research and with them, the promise of longer and healthier lives. The authors explicate the Translation Gap faced by early stage biotech companies, the result of problematic technology transfer and investment practices, and provide specific prescriptions for improving translation of important discoveries into safe and effective therapies. In Preserving the Promise, Dessain and Fishman build on their collective experience as company founders, healthcare investor (Fishman) and physician/scientist (Dessain). The book offers a forward-looking, critical analysis of "conventional wisdom" that encumbers commercialization practices. It exposes the self-defeating habits of drug development in the Valley of Death, that waste money and extinguish innovative technologies through distorted financial incentives. Explains why translation of biotech discovery into medicine succeeds so infrequently that it’s been dubbed the Valley of Death Uncovers specific decision-making strategies that more effectively align incentives, improving clinical and financial outcomes for investors, inventor/entrepreneurs, and patients Examines the critical, early stages of commercialization, where technology transfer offices and Angels act as gatekeepers to development, and where tension between short-term financial and long-term clinical aspirations sinks important technologies Deconstructs the forces driving biotech, recasts them in a proven conceptual framework, and offers practical guidance for making the system better
Author: Dimitrios Iliopoulos
Publisher: Createspace Independent Publishing Platform
ISBN: 9781539874386
Category :
Languages : en
Pages : 214
Get Book
Book Description
Janet Yellen, the Fed Chair, recently said that the valuations of small-cap biotechnology companies are substantially stretched. Biotechnology is a relatively new science and during the last few years there is an increasing number of new biotech start-up companies and also M&A activity between biotech start-ups and large biotechnology and pharmaceutical companies. Few years ago, we observed one of the largest acquisitions in the biotech sector, by having Amgen buying Onyx Pharmaceuticals for more than $9 billion dollars. More recently, Moderna Therapeutics, a biotech company developing mRNA therapeutics, broke the record of VC funding, raising $450 million dollars in a single round of funding, without having a product in the market. All these recent events raise an important question: what are the valuation financial models used in the biotechnology industry? How could we value a company having negative cash flows for several years, without any product in the market? How do we value a company developing a CRISPR therapeutics currently in the preclinical level? Is there any difference on valuating a phase II drug against arthritis vs a phase II anti-cancer drug? This book is aiming to answer these essential questions by describing the key aspects of the drug discovery process, including novel financial models used for valuation of biotech companies. Furthermore, we have created new biotech valuation cases providing to the reader a practical guide for valuation of any biotech product or company.
